BioSpectrum the business of Bio & Health Sciences ASIA EDITION

Life science leaders to converge at Biologics World China in Nov

July 31, 2012 | News | By BioSpectrum Bureau

Life science leaders to converge at Biologics World China in Nov



Singapore: China is undergoing major healthcare reform and the bio and pharmaceutical market is expected to maintain double digit growth of approximately 20 percent to reach over $35 billion by 2015. It is predicted that this rapid growth will contribute to China becoming the world's second largest pharmaceutical market over the next three years.

According to ChinaBio Today, China's Minister of Health commented that China plans to spend $11.8 billion in order to increase biopharma innovation in its 13th Five-Year Plan, which covers the period 2016-20. That is almost double the $6.3 billion it will spend in the current period, the 12th Five-Year Plan for 2011-15, bringing its ten-year total to over $18 billion.

Biologics World China, which facilitates innovation and manufacturing of affordable and high quality biologic drugs and vaccines in China and which is in its third year running, continues to provide an industry-focused platform in China, bringing together decision makers across C level management, R&D and manufacturing in the realms of biologic drugs, biosimilars, vaccines and blood/plasma products. The vent will be held from November 5-7, 2012, and will see over 300 industry experts gather to share best practices and exchange perspectives on raising benchmark of quality, stimulating innovation and increasing global competitiveness.

Regulatory guidelines, parameters for biosimilars, case studies on cell lines and process development, scale-up and downstream methodologies, single-use technology and a showcase of novel biologics and vaccines will be featured in the 2012 show.

This conference was developed with the support of the advisory board, comprising of top industry professionals, including Dr Joe Zhou, CEO, Genor BioPharma, China; Dr Su Chen, CEO, Chengdu Kanghong Biotechnology, China; Dr Michael Yu, CEO, Innovent Biologics, China; Dr Yining Zhao, senior director and Asia strategy lead, strategic planning group, worldwide R&D, Pfizer; Dr Scott Liu, CEO, Henlius Biopharmaceuticals, China; Dr Li Shi, CEO, Zerun Biotechnology, China; and Dr Zhang Zheru, VP, R&D, Celltrion, Korea.